Italy cancels marketing approval for Bortezomib Mylan at company's request
Italy's medicines agency AIFA has cancelled the marketing permission for the human medicine Bortezomib Mylan. The license holder asked for the cancellation and gave up the authorization voluntarily. The official notice appeared in Italy's Official Gazette (Gazzetta Ufficiale) on 31 October 2026.
This summary was generated by AI; the official source prevails.
What does it mean?
Italy's medicines agency has withdrawn the permission that let the medicine Bortezomib Mylan be sold in Italy. The company that held that permission asked for it to be cancelled, so the product is no longer approved under that name here. The excerpt does not say when the cancellation takes effect.
Who is affected?
The company that holds the Bortezomib Mylan authorization in Italy, and people who buy or use this medicine there.
What changes?
Before, Bortezomib Mylan was authorized for sale in Italy; now that authorization has been cancelled.